Lonza Biologics Plant Expansion

Eculizumab was approved by the US FDA in March 2007 and acts against complement component C5.

Eculizumab was approved by the US FDA in March 2007 and acts against complement component C5.


client logon
Home
Products & Services
Company A-Z
White Papers
Jobs & Careers
Press Releases
Advertise With Us
Events & Exhibitions
Newsletter
New On This Site
About Us
Atom FeedRSS Feed
What is RSS?